Breast carcinoma detection

Frankfurt, O. S., Robb, J. A., Sugarbaker, E. V., and Villa, L. (1997) Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA relation to bcl-2 expression, hormone receptors, and lymph node me-tastases. Clin. Cancer Res. 3(3), 465 471. 

HER-2 (c-erb-2) Breast carcinoma, detection of HER-2 overexpression for immunotherapy Ovarian and endometrium carcinomas Breast epithelium... 

Vassallo J, Pinto GA, Alvarenga JM, et al. Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl. Immunohistochem. Mol. Morphol. 2004 12 177-182. 

Tsuda, H., Tani, Y, Hasegawa, T., and Fukutomi, T. 2001. Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by southern blot hybridization in breast carcinoma. Pathol. Internat. 51 26-32. 

Figure 4. A detection method for chromogenic visualization of dual-color FISH signals with anti-hapten antibody. After FISH-staining with two different fluorochromes such as FITC and Texas Red (a and inset photo a HER2 FISH analysis in breast carcinoma), archival tissue can be immunohistochemically detected using the corresponding anti-fluorochrome antibodies and two different chromogens (b and inset photo b HER2 CISH analysis in the same lesion as in the upper photo).

Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohis-tochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991 83(2) 111-116. 

CA 15-3, CA 549, and CA 27.29 assays detect a high molecular weight glycoprotein mucin expressed by the mammary epithelium, known as episialin. The circulating episialin antigen is a heterogeneous molecule. CA 15-3, CA 549, and CA 27.29 assays detect similar yet different epitopes on the episialin. The main differences are the antibodies used for detection. They are used as markers for breast carcinoma. 

CA 27.29 is detected by a monoclonal antibody, B27.29, that is produced against an antigen in ascites of patients with metastatic breast carcinoma. The minimum epitope to which B27.29 reacts is the 8 amino acid sequence (SAPDTRPA) within the 20 amino acid tandem repeating sequence of the mucin core. The reactive sequence of the B27.29 overlaps with the sequence of DF3 used in the CA 15-3 assay. In inhibition studies using labeled MAb, B27.29 effectively competes with DF3 for binding to both CA 27.29 and CA 15-3 antigens. "... 

Haagensen Jr DE, Mazoujian G, Holder Jr WD, et al. Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann Surg. 1977 185 279-285. 

The positive predictive value and specificity for detection of breast carcinoma with GCDEP15 have been reported to be up to 99%. The sensitivity for the GCDFP15 antibodies has been reported to be as high as 75% for tumors with apocrine differentiation, 732 the overall sensitivity is 55%, and only 23% for tumors without apocrine differentiation. The sensitivity is even worse when it comes to core biopsy, since the pattern of staining for GCDFP15 is often patchy. 

Tsuda H, AkiyamaF, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001 92 2965-2974. 

Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 2002, 82, 1007-1014. 

---